Lexeo Therapeutics Inc (NASDAQ:LXEO)’s traded shares stood at 0.7 million during the last session, with the company’s beta value hitting 3.90. At the close of trading, the stock’s price was $2.86, to imply a decrease of -4.35% or -$0.13 in intraday trading. The LXEO share’s 52-week high remains $19.50, putting it -581.82% down since that peak but still an impressive -3.85% since price per share fell to its 52-week low of $2.97.
Analysts have given a consensus recommendation of Buy for Lexeo Therapeutics Inc (LXEO), translating to a mean rating of 1.14. Of 2 analyst(s) looking at the stock, 0 analyst(s) give LXEO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.78.
Lexeo Therapeutics Inc (NASDAQ:LXEO) trade information
After registering a -4.35% downside in the last session, Lexeo Therapeutics Inc (LXEO) has traded red over the past five days. The 5-day price performance for the stock is -26.48%, and -45.11% over 30 days. With these gigs, the year-to-date price performance is -56.53%.
The extremes give us $28 and $28 for target low and target high price respectively. As such, LXEO has been trading -879.02% off suggested target high and -879.02% from its likely low.
LXEO Dividends
Lexeo Therapeutics Inc has its next earnings report out in April. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
We also have Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Janus Henderson Global Life Sciences Fund as the top two Mutual Funds with the largest holdings of the Lexeo Therapeutics Inc (LXEO) shares. Going by data provided on Sep 30, 2024 , Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund holds roughly 1.53 shares. This is just over 4.61% of the total shares, with a market valuation of $4.36 million. Data from the same date shows that the other fund manager holds a little less at 731.18, or 2.21% of the shares, all valued at about 2.09 million.
